Cellebrite DI Ltd. $CLBT Stock Holdings Raised by King Luther Capital Management Corp

King Luther Capital Management Corp lifted its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 28.6% in the 3rd quarter, Holdings Channel.com reports. The fund owned 829,337 shares of the company’s stock after buying an additional 184,290 shares during the quarter. King Luther Capital Management Corp’s holdings in Cellebrite DI were worth $9,338,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the company. Light Street Capital Management LLC lifted its position in Cellebrite DI by 104.8% in the 2nd quarter. Light Street Capital Management LLC now owns 1,312,755 shares of the company’s stock valued at $19,166,000 after acquiring an additional 671,830 shares in the last quarter. Roubaix Capital LLC boosted its stake in Cellebrite DI by 108.1% during the 1st quarter. Roubaix Capital LLC now owns 303,215 shares of the company’s stock valued at $4,178,000 after purchasing an additional 157,536 shares during the last quarter. Lazard Asset Management LLC bought a new stake in shares of Cellebrite DI in the 1st quarter worth $2,134,000. Nine Ten Capital Management LLC increased its holdings in shares of Cellebrite DI by 19.8% in the 2nd quarter. Nine Ten Capital Management LLC now owns 4,126,808 shares of the company’s stock worth $60,251,000 after purchasing an additional 682,933 shares in the last quarter. Finally, Principal Financial Group Inc. increased its holdings in shares of Cellebrite DI by 33.9% in the 1st quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company’s stock worth $29,712,000 after purchasing an additional 545,334 shares in the last quarter. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CFO David Barter sold 12,134 shares of Cellebrite DI stock in a transaction that occurred on Friday, October 16th. The stock was sold at an average price of $11.21, for a total transaction of $136,022.14. Following the sale, the chief financial officer owned 322,085 shares of the company’s stock, valued at approximately $3,610,572.85. This trade represents a 3.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CRO Marcus Jewell sold 12,562 shares of Cellebrite DI stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $11.24, for a total value of $141,196.88. Following the sale, the executive directly owned 427,128 shares in the company, valued at $4,800,918.72. This trade represents a 2.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 56,909 shares of company stock worth $641,890. 5.70% of the stock is currently owned by corporate insiders.

Key Cellebrite DI News

These are some of the CLBT news items that stood out recently:

• Positive Sentiment: Third-quarter revenue was $149.02 million, above the $145.83 million analyst estimate. Cellebrite reported $0.17 in EPS; estimates vary, with one source calling that in line and another comparing it with a lower $0.09 consensus. Cellebrite third-quarter results
• Neutral Sentiment: Full-year 2026 revenue guidance of $553 million–$558 million includes the $556.8 million consensus estimate, suggesting the annual outlook was broadly on target. Cellebrite third-quarter results
• Negative Sentiment: Fourth-quarter revenue guidance of $145 million–$150 million was below the $151.6 million consensus estimate. The softer near-term outlook likely weighed on shares despite the quarterly revenue beat. Cellebrite third-quarter results

Cellebrite DI Stock Performance

Shares of NASDAQ:CLBT opened at $10.89 on Friday. The stock has a market capitalization of $2.72 billion, a price-to-earnings ratio of 49.50, a PEG ratio of 1.95 and a beta of 1.06. The stock’s 50-day simple moving average is $11.61 and its two-hundred day simple moving average is $13.24. Cellebrite DI Ltd. has a 52-week low of $9.58 and a 52-week high of $19.98.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings results on Thursday, November 12th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.08. Cellebrite DI had a net margin of 11.43% and a return on equity of 15.58%. The business had revenue of $149.02 million for the quarter, compared to analysts’ expectations of $145.83 million. As a group, equities analysts forecast that Cellebrite DI Ltd. will post 0.37 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Weiss Ratings cut Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, August 27th. DA Davidson reaffirmed a “buy” rating and set a $15.00 price objective on shares of Cellebrite DI in a research report on Tuesday, September 15th. Needham & Company LLC reduced their price objective on Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a report on Friday, August 14th. Lake Street Capital decreased their target price on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a research note on Friday, August 14th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.62.

Cellebrite DI Profile

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.